Clinical and bacteriological efficacy of sequential intravenous to oral moxifloxacin in hospitalised patients with severe complicated skin and skin structure infections due to Enterobacteriaceae
Abstract number: 1733_1519
Bogner J.R., Choudhri S.H., Arvis P., Pertel P., Breilmann J-M.
Objectives: Enterobacteriaceae species are an important cause of cSSSI in patients with underlying comorbid illnesses such as diabetes mellitus, and require empiric therapy with broad spectrum antimicrobials. Pooled data from 2 cSSSI trials were used to compare the clinical and microbiological efficacy of sequential intravenous (IV)/oral (PO) moxifloxacin (MXF) with comparator (COMP) therapy in patients with cSSSI due to Enterobacteriaceae.
Methods: Data were pooled from 2 trials of sequential MXF (400 mg q.d. IV/PO) in the treatment of cSSSI in hospitalised patients. COMP treatment consisted of IV piperacillin/tazobactam followed by PO amoxicillin/clavulanate and sequential IV/PO amoxicillin/clavulanate.
Results: The 2 trials enrolled 1421 patients (712 MXF, 709 COMP) of which 999 were valid per protocol (495 MXF, 504 COMP). Of these patients, 286 (57.8%) MXF and 291 (57.7%) COMP-treated subjects were also microbiologically valid. Of these, 87 (30.4%) MXF and 77 (26.5%) COMP-treated subjects had Enterobacteriaceae isolated from their skin infection sites. The following organisms were isolated (MXF, COMP): E. coli (38, 33), Klebsiella spp. (14, 10), Proteus spp. (14, 16), Morganella spp. (1, 3), Providencia spp. (2, 2), Serratia marcescens (4, 2) and Enterobacter (14, 11). The overall clinical and bacteriological success rates at test-of-cure among per protocol valid patients who had a positive skin culture for Enterobacteriaceae were 65/87 (74.7%) and 64/87 (73.6%) for MXF and 56/77 (72.7%) and 56/77 (72.7%) for COMP-treated patients.
Conclusions: Enterobacteriaceae were cultured frequently from hospitalised patients with cSSSI. Monotherapy therapy with IV/PO MXF had similar clinical and bacteriological efficacy as the standard treatment regimens in the management of cSSSI due to Enterobacteriaceae.
Research funding: Bayer HealthCare Pharmaceuticals.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|